Financial Data and Key Metrics Changes - The company reported full-year GAAP net earnings of $208 million for 2025, a significant increase from $54.8 million in 2024 [19] - Full-year adjusted net earnings were $258.8 million, up approximately 17% from $221.6 million in 2024 [19] - Full-year net earnings per share (EPS) was $0.27, with adjusted net EPS of $0.34, exceeding guidance by $0.02 [5][22] - Operating expenses as a percentage of gross revenue decreased from approximately 38% in 2024 to roughly 36% in 2025 [6] Business Line Data and Key Metrics Changes - The increase in adjusted net earnings was primarily driven by $10.3 million from new utility rates implemented across various systems [20] - New utility rates contributed $41.6 million of benefit from approved rate implementations throughout the year [22] - The regulated services group growth was supported by new rate implementations, favorable weather, and lower interest expenses [24] Market Data and Key Metrics Changes - The company operates in high-quality jurisdictions with attractive regulatory mechanisms, including tracker mechanisms and multi-year rate plans [16] - Recent legislative and regulatory developments in states like Missouri and Arizona are enhancing investment recovery [17] Company Strategy and Development Direction - The company aims to become a premium pure-play regulated utility, focusing on operational discipline and regulatory strategy execution [5][10] - A centralized capital projects team is being implemented to improve execution and performance [9] - The capital expenditure outlook for 2026-2028 is approximately $3.2 billion, with a focus on safety, reliability, and service improvements [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 earnings guidance, reaffirming the adjusted net EPS estimate in the range of $0.35-$0.37 [30] - The effective tax rate for 2027 is now expected to be in the mid-to-high 20% range, impacting future earnings projections [11][30] - Management emphasized the importance of operational excellence and regulatory engagement to drive sustainable earnings growth [32] Other Important Information - The company strengthened its balance sheet by using net proceeds from the sale of its renewable business to retire approximately $1.6 billion of debt [7][27] - Total debt stands at approximately $6.5 billion, with a solid investment-grade credit rating [28] Q&A Session Summary Question: What are the largest drivers behind the revised 2027 guidance? - The effective tax rate moved from low to mid-twenties to mid to high twenties, resulting in a deduction of about $0.03 per share in EPS [36] Question: What are the largest levers the business can pull in the near term? - The focus is on regulatory engagement and leveraging a strong balance sheet to pursue organic growth opportunities [38] Question: Can you provide an update on the additional opportunities mentioned? - The growth story starts with organic growth within existing jurisdictions, with a disciplined approach to potential M&A opportunities [46] Question: How is the company progressing on customer metrics for the Missouri rate case? - The company believes it has satisfied the customer metrics and is in the process of validating this with the commission [96]

Kingstone Companies (NasdaqCM:KINS) Q4 2025 Earnings call March 06, 2026 08:30 AM ET Speaker2Greetings, welcome to the Kingstone Companies' fourth quarter and full year 2025 earnings conference call. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Stefan Norba, Kingstone investor relations representative. Thank you. You may begin.Speaker5Thank you and good morning, everyone. Joining us on the call today will be President and Chief Executive Officer, Mer ...

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses for 2025 were $148 million, lower than in 2024 due to many late-stage trials nearing completion [6] - Cash position strengthened to approximately $1.4 billion, allowing for accelerated global development and exploration of in-licensing and M&A opportunities [4][7] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and SULANDA accounted for 11% of total 2025 in-market sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting overall performance [9] - China sales under the brand name ELUNATE experienced a -13% decline in the first half but rebounded with 33% growth in the second half [9] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing an addressable market of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of ATTC programs while exploring business development opportunities [25] - Focus on expanding the hematology portfolio with new products and establishing a dedicated sales and marketing team for this specialized area [11][71] - The strategy includes potential partnerships for the ATTC platform to validate and enhance its value [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with oncology revenue guidance set between $330 million and $450 million, reflecting strong growth expectations [7][25] - The company anticipates continued growth from new indications and the global expansion of FRUZAQLA [31] - Management highlighted the importance of maintaining a balance between existing commercial products and emerging opportunities from the ATTC platform [52] Other Important Information - The company has advanced two ATTC programs into clinical trials, with significant market potential anticipated [4] - The SAFFRON and SANOVO readouts are expected in mid-2026, which are critical for future growth [31][24] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and continued recovery in sales [30][31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [31][36] Question: Can you provide details on the ATTC platform candidates? - A251 is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [31] Question: How are commercial dynamics expected to stabilize in 2026? - Management noted that turnover rates have decreased and the sales team has been restructured to focus on top-tier hospitals, which should improve performance [41][42] Question: What is the impact of MET testing adoption on savolitinib? - No additional information was provided on the influence of MET testing adoption on savolitinib uptake [48] Question: What is the partnering strategy for the ATTC platform? - The company is considering licensing out some programs while maintaining control over others to maximize long-term value [50] Question: What is the guidance for R&D expenses this year? - Management indicated a desire to ramp up R&D investment to a range of $250 million to $300 million [60] Question: Can you elaborate on the in-licensing and M&A strategy? - The company is open to in-licensing late-stage commercial assets or complementary assets, given its strong cash position [63] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [71]

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses decreased to $148 million in 2025, lower than in 2024 due to many late-stage trials nearing completion [6] Business Line Data and Key Metrics Changes - Ex-China sales of FRUZAQLA grew by 26% year-over-year, reaching $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and Surufatinib accounted for 11% of total EMARC sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting growth [9] - China sales under the brand name ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [9] - The ITP market in China is significant, with over 250,000 actively treated patients, representing a market potential of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [4][26] - Focus on building a strong hematology portfolio, with the first-in-class treatment for EZH2 mutation approved [11] - The company is pursuing partnerships with multinational companies to validate and add value to its ATTC platform [48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [26] - The oncology revenue guidance for 2026 is projected to be between $330 million and $450 million, reflecting strong growth expectations [7][26] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [71] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated development and exploration of business opportunities [4] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20][21] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong momentum and growth from new indications, with expectations for continued recovery [31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [32] Question: Can you provide details on the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2-expressing solid tumor patients, focusing on post-HER2 treatment settings [32] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that the impact from Medicare changes has already been reflected in 2025 results, but they anticipate continued growth in ex-U.S. markets [71] Question: What is the strategy for partnering with the ATTC program? - The company is open to licensing out some programs to accelerate development while maintaining control over others for long-term value [48] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [69]

Financial Data and Key Metrics Changes - The company reported a revenue of $366 million for the period, reflecting a 26% increase compared to the previous year [1]. Business Line Data and Key Metrics Changes - Specific business line performance details were not provided in the available content, indicating a lack of clarity on individual segment contributions [5]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were mentioned in the provided content [5]. Company Strategy and Development Direction - The company is focusing on first-in-class products and has several NDA submissions planned for 2025 and 2026, indicating a strong pipeline and commitment to innovation [2][4]. Management Comments on Operating Environment and Future Outlook - Management has not provided detailed comments on the operating environment or future outlook in the available content [5]. Other Important Information - The company is involved in various clinical trials and has multiple products in development, including those targeting specific biomarkers [3][4]. Q&A Session Summary Question: What is the guidance for 2026? - The company provided a revenue guidance of $148 million for 2025 and an estimated range of $200 million to $300 million for 2026 [6].

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [4] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [4] - R&D expenses for 2025 were $148 million, lower than 2024 as many late-stage trials were nearing completion [4] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [2] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [2] - ORPATHYS and Surufatinib accounted for 11% of total 2025 EMARC sales but faced competition, impacting their performance [9] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds due to Medicare Part D redesign, impacting overall performance [8] - In China, ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [8] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing a market of $500 million to $700 million [18] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [3] - A focus on building a strong hematology portfolio is evident, with the launch of the first-in-class treatment for EZH2 mutation and follicular lymphoma [10] - The company is committed to maintaining a balance between R&D investments and commercial income generation [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [24] - The oncology revenue guidance for 2026 is projected between $330 million and $450 million, reflecting strong growth expectations [5] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [70] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated investments in ATTC development [3] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and recovery momentum [28][29] Question: Why was the SAFFRON readout delayed? - The SAFFRON readout is now expected in mid-2026 [30] Question: What is the indication for the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [30] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that while there were impacts in 2025, they anticipate continued growth in the U.S. and other markets [70] Question: What is the strategy for the ATTC platform? - The company is considering potential licensing out of some programs while maintaining control over others to maximize long-term value [46]

Financial Data and Key Metrics Changes - Net sales increased over 17% year-over-year to nearly $136 million, reflecting strong performance [5][17] - EBITDA rose nearly 21% to $16.8 million, with adjusted EPS increasing from $0.03 to $0.08 [6][19] - Operating cash flow grew by more than $30 million year-over-year, reaching over $20 million in the quarter [6][19] - Gross margin improved by 210 basis points to 26.2%, driven by increased production volume and lower promotion costs [18] Business Line Data and Key Metrics Changes - Handgun unit shipments increased by 28%, while NICS data showed a decline of 2.2%, indicating market share growth [7][8] - Long gun shipments decreased by 25%, with NICS down 5.6%, attributed to prior year channel fill and product mix [8][9] - New products accounted for 44% of handgun shipments and 28% of long gun shipments, showcasing innovation's impact on sales [9] Market Data and Key Metrics Changes - Distributor inventory levels remained flat at approximately nine weeks of supply, indicating stable demand [12][17] - The overall market for firearms showed a stable environment, with expectations for continued strong demand [17][21] Company Strategy and Development Direction - The company is focused on innovation and maintaining pricing power, with a strategic emphasis on product development and market trends [5][16] - The Smith & Wesson Academy is exceeding expectations, contributing to growth in both consumer and law enforcement channels [13][14] - The company aims to reduce debt and strengthen its financial position, ending Q3 with $75 million in debt [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the brand's strength and product assortment, anticipating Q4 sales growth of 10%-12% over the previous year [21] - The company expects to see an increase in gross margin in Q4 due to higher production and demand [21] - Management highlighted a healthy pipeline for law enforcement sales, indicating a focus on this segment for future growth [33][34] Other Important Information - The company paid $5.8 million in dividends and ended the quarter with $23.5 million in cash and investments [20] - Capital spending for the year is expected to be between $25 million and $30 million [20] Q&A Session Summary Question: Recent pricing changes - Management confirmed a price increase of approximately 3% effective January 1, with no pushback from distributors or consumers [24][25] Question: Strength in handgun sales - Management attributed strong handgun sales to successful product refreshes and market trend alignment, particularly in the polymer pistol line [26][28] Question: Long gun market strategies - Management acknowledged challenges in the long gun market but noted potential opportunities in the hunting category and SBRs [29][30] Question: Law enforcement sales opportunities - Management emphasized the focus on law enforcement sales, highlighting a healthy pipeline and ongoing innovation in this area [32][34]

Financial Data and Key Metrics Changes - Consolidated revenue increased by 26% to $134 million in Q4 2025 compared to Q4 2024 [3] - Operating loss was $21 million in Q4 2025, improved from a loss of $49 million in Q4 2024, which included a $26 million non-cash impairment charge [3][20] - Full year 2025 revenue was $447.6 million, up 23% compared to full year 2024 [19] Business Segment Data and Key Metrics Changes - Media segment revenue declined by 32% to $45.8 million in Q4 2025 compared to Q4 2024, with full year revenue down 20% to $176.7 million [12] - Advertising Technology & Services (ATS) segment revenue more than doubled, reaching $88.6 million in Q4 2025, a 123% increase compared to Q4 2024 [15][8] - ATS operating profit was $12 million in Q4 2025, compared to $2 million in Q4 2024, marking a 464% increase [10][18] Market Data and Key Metrics Changes - Local advertising revenue increased by 4% in Q4 2025, while national advertising revenue decreased by 5% [4] - Monthly active advertisers in local operations decreased by 3%, but revenue per monthly active advertiser increased by 8% [4] Company Strategy and Development Direction - The company is focused on increasing local sales capacity and expanding digital sales operations in the media segment [11] - In the ATS segment, investments are being made to enhance technology and increase sales capacity [11] - The company aims to optimize organizational structure and reduce expenses to align with revenue growth [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the political advertising environment for 2026, highlighting the importance of the Latino vote in upcoming elections [27][28] - The company is positioned well for political spending, with several key races in its markets [27] - Management acknowledged the need for continued improvement in operating performance and profitability, particularly in the media business [3][21] Other Important Information - Corporate expenses decreased by 13% in Q4 2025 compared to Q4 2024, and by 28% for the full year [21] - The company has a strong balance sheet with over $63 million in cash and marketable securities at year-end [22] - A dividend of $0.05 per share was approved for the first quarter of 2026, totaling approximately $4.6 million [23] Q&A Session Summary Question: Outlook for political revenue in 2026 - Management is optimistic about a strong political spending environment in 2026, emphasizing the critical role of the Latino vote [27][28] Question: Status of renewing the affiliation agreement with TelevisaUnivision - The affiliation agreement runs through December 31, 2026, and management expects to renew it [29]

Financial Data and Key Metrics Changes - Revenue for the full year 2025 was $1.6 million, down from $6.3 million in 2024, reflecting a transition away from legacy product lines [16] - Gross loss for the year was $27.7 million, an improvement of 39% compared to a loss of $45.4 million in 2024 [17] - Total operating expenses decreased 33% year-over-year to $29.7 million, down from $44.4 million [17] - Net loss for the full year was $63.4 million compared to $86.2 million in 2024, an improvement of 26% [18] - Adjusted EBITDA improved 38% year-over-year, reflecting significant cost reductions across the business [22] Business Line Data and Key Metrics Changes - The company is refocusing on the Energy Base product, leading to a decline in revenue from legacy units [16] - Deliveries of legacy units primarily to related parties and engineering services contributed to the revenue recognized during the year [17] Market Data and Key Metrics Changes - Demand from AI data centers is projected to increase 165% by 2030, indicating a growing market for long-duration energy storage [14] - The grid will need to deploy 8 TWh of long-duration storage by 2040 to meet clean energy targets, highlighting the market opportunity [14] Company Strategy and Development Direction - The company aims to commercialize the Energy Base product in 2026, with significant revenue expected in 2027 and 2028 from tier one customers [30] - The acquisition of VoltStorage enhances the company's technological capabilities and strengthens its intellectual property portfolio [11] - The company is exploring different financial structures for the Salt River Project, which includes a 10-year PPA agreement [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial momentum, citing signed agreements with significant counterparties [26] - The financial performance is improving across key metrics, with structural cost reductions being a focus [27] - The company is strategically planning future capital raises, indicating a thoughtful approach to financial management [40] Other Important Information - The company has made leadership changes, including the appointment of a permanent CFO and a new Chief Commercial Officer [11] - As of December 31, 2025, the company had $14.5 million in unrestricted cash and cash equivalents, indicating a solid liquidity position [23] Q&A Session Summary Question: Outlook for revenue ramp-up associated with key projects - The focus for 2026 will be on commercializing the Energy Base, with significant revenue expected in 2027 and 2028 [30] Question: Ownership structure for the Salt River Project - The company is still in the planning phase regarding ownership and expects to start recognizing revenues in 2028 [32] Question: Potential for follow-on deployments after the pilot project - There is potential for a follow-on project with SRP, with operational data expected by mid-2028 [34] Question: Plans for repaying the second tranche of promissory notes and future capital raises - The financial runway has improved, and the company is being strategic about future capital raises [39]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported revenues of $100.6 million, a 5% increase from $95.5 million in 2024, marking the first time achieving the $100 million milestone [14] - In Q4 2025, revenues were $27.1 million, a sequential increase of 9% from $24.8 million in Q3 2025, but a year-over-year decrease of $3.2 million [15] - Average Revenue Per User (ARPU) increased to $0.46 for Q4, up 2% sequentially from Q3 2025 [16] - Adjusted EBITDA loss for Q4 was $16 million, compared to a loss of $13.4 million in Q4 2024, while the full year adjusted EBITDA loss improved to $74.3 million from $92.1 million in 2024 [17] Business Line Data and Key Metrics Changes - Audience monetization revenues decreased by $5.5 million in Q4, partially offset by a $2.7 million increase in subscription and licensing fees [15] - The company introduced Rumble Shorts, which achieved over 1 million unique video views in a single day shortly after launch, indicating strong user engagement [6][12] Market Data and Key Metrics Changes - Monthly Active Users (MAUs) reached 52 million in Q4, an 11% sequential increase driven primarily by international growth [16] - The company noted that international monetization remains low compared to the U.S. market, indicating potential for future growth [31] Company Strategy and Development Direction - The company is focused on aggressive growth, particularly in video advertising and cloud services, with a strategic emphasis on capturing ad dollars from major brands [3][23] - The acquisition of Northern Data is expected to close in Q2 2026, which the company believes will be transformative for its revenue profile [9][11] - The company plans to leverage a $50 million per year advertising deal with Tether to attract major influencers and podcasters to the platform [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth returning as the company enters a midterm election year, with a favorable advertising market and strong user engagement [5][11] - The company anticipates that the advertising commitment from Tether will ramp up significantly in the second and third quarters of 2026 [11][18] Other Important Information - The company ended Q4 with total liquidity of $256.4 million, including $237.9 million in cash and cash equivalents [18] - The company is actively working on building a professionalized sales operation to convert its reach into high-value brand partnerships [7] Q&A Session Summary Question: How does the addition of Greg Sherrill as President of Sales change the go-to-market strategy? - Management indicated that the strategy will shift to a more proactive approach in securing ad dollars from major agencies, moving from a defensive to an offensive strategy [21][23] Question: How might Rumble Shorts serve as a catalyst for advertising revenue? - Management plans to initially keep advertising off Rumble Shorts to maximize growth, with a strategy to integrate ads later in the year [24][25] Question: What is the current relationship with Dan Bongino? - Management confirmed that Dan Bongino's content is now exclusively available on Rumble, differing from prior arrangements [26] Question: What are the drivers behind advertising sales growth? - Management expects ad sales to ramp up later in 2026, with a focus on securing bookings and monetizing inventory through new ad units [41] Question: What is the status of the Northern Data acquisition? - Management confirmed that the acquisition is on track to close in Q2 2026, with all processes running on schedule [34] Question: How will Tether's $150 million commitment be prioritized? - Management stated that Tether will be treated like any other customer, with a focus on fulfilling their demand while also accommodating other clients [51][53]